Agilent and Ubix Therapeutics Partner for Cancer Research in South Korea
Agilent Technologies has entered into an agreement with Ubix Therapeutics to advance targeted cancer therapy research in South Korea. The collaboration will focus on protein degradation and antibody-drug conjugates.
Agilent Technologies has signed a five-year Memorandum of Understanding (MOU) with South Korea-based Ubix Therapeutics to accelerate research and development in targeted cancer therapies.
The partnership will focus on developing targeted protein degradation (TPD) and antibody-drug conjugate (ADC) therapies. This initiative combines Ubix's proprietary Degraducer platform with Agilent's extensive capabilities in cancer research and technology.
TPD and ADC approaches are rapidly emerging as significant modalities in precision oncology, addressing previously undruggable targets. Agilent's advanced analytical technologies, including its InfinityLab Bio LC portfolio, LC/MS systems, and BioTek product families, will support the research efforts.
This collaboration aims to meet unmet patient needs and improve access to innovative treatments. Seo Bo-Kwang, CEO of Ubix Therapeutics, stated the partnership will enhance their ability to deliver next-generation therapies. You Jae Soo, South Korea country general manager at Agilent, highlighted the company's commitment to furthering biomedical advancement in the region.